medigraphic.com
Instituto Nacional de Salud Pública

2012, Number 5

<< Back Next >>

salud publica mex 2012; 54 (5)

Towards the eradication of poliomyelitis: Mexico’s achievements and challenges

Esteve-Jaramillo A, López-Collada VLR

Language: Spanish
References: 34
Page: 537-543
PDF size: 251.27 Kb.


ABSTRACT

Since the strategies to eradicate polio were implemented, the incidence of paralytic polio has dropped dramatically. Four main strategies have greatly contributed: a) High immunization coverage rate with oral polio vaccine (OPV), b) Supplementary immunization activities during the National Immunizations Days c) An effective epidemiological surveillance system for acute flaccid paralysis (AFP) and d) Intensified immunization activities in high risk areas. Three countries remain polio endemic, nevertheless, any country has a potential risk of the virus importation from one of these endemic areas; an accidental release of poliovirus from a research or clinical laboratory, or from having a circulating vaccine-derived poliovirus in the environment. The present document aims to provide an historical background that made possible the disease elimination in Mexico. Moreover, we discuss the challenges that every country needs to face in order to achieve a polio-free world.


REFERENCES

  1. Pan American Health Organization. Director announces campaign to eradicate poliomyelitis from the Americas by 1990. Bull Pan Am Health Organ 1985;19:213

  2. World Health Assembly. Global eradication of poliomyelitis by the year 2000. Geneva: World Health Organization, 1988; resolution WHA41.28.

  3. Robertson SE, Chan C, Kim-Farley R, Ward N. Worldwide status of poliomyelitis in 1986, 1987 and 1988, and plans for its global eradication by the year 2000.World Health Stat Q 1990;43:80-90.

  4. Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication--the Americas, 1994. MMWR Morb Mortal Wkly Rep 1994; 43:720-722.

  5. Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication--Western Pacific Region, October 2000. MMWR Morb Mortal Wkly Rep 2001; 50:1-3.

  6. Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication--European Region, June 2002. MMWR Morb Mortal Wkly Rep 2002;51:572-574.

  7. World Health Organization. Country Office Tajikistan; WHO Regional Office for Europe; European Centre for Disease Prevention and Control. Outbreak of poliomyelitis in Tajikistan in 2010: risk for importation and impact on polio surveillance in Europe? Euro Surveill 2010;15.

  8. Centers for Disease Control and Prevention (CDC). Outbreaks following wild poliovirus importations. Europe, Africa, and Asia, January 2009-September 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1393-1399.

  9. Smith J, Leke R, Adams A, Tangermann RH. Certification of polio eradication: process and lessons learned. Bull World Health Organ 2004; 82:24-30.

  10. Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc 1957;164:1216-1223.

  11. Sabin AB. Status of field trials with an orally administered, live attenuated poliovirus vaccine. J Am Med Assoc 1959;171:863-868.

  12. Ramos-Alvarez M, Bustamante ME, Alvarez Alba R. The use of the Salk vaccine, in the polio live virus, in Mexico: Study Results. Bol Oficina Sanit Panam 1961; 50:305-322.

  13. Consejo Nacional de Vacunación. Manual de vacunación 2008-2009. México, D.F: CONAVA 2008: 405.

  14. Instituto Nacional de Salud Pública. Encuesta Nacional de Cobertura de Vacunación. Cuernavaca, Morelos: INSP, 2010: 54.

  15. Díaz-Ortega J, Valdespino JL, Zárate ML, Camacho L. Seroconversión a la vacuna Sabin trivalente en niños menores de 4 años de edad. Bol Hosp Inf Mex 1989; 46:517-520.

  16. Ruiz-Gómez J, Tapia-Conyer R, Salvatierra B, et al. Seroepidemiología de la poliomielitis en México. Salud Publica Mex 1992; 34:168-176.

  17. Ruiz-Gómez J, Valdespino JL, Olaiz-Fernández G, Arias-Toledo E, Sepúlveda J. Seroprevalencia de anticuerpos contra el poliovirus 1 en niños mexicanos. Salud Publica Mex 2007;49:S361-S369.

  18. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol 2003;13(5):277-291.

  19. Aylward RB, Sutter RW, Heymann DL. Policy: OPV cessation – the final step to a ‘polio-free’ world. Science 2005; 310: 625-626.

  20. Global Polio Eradication Initiative. Framework for National Policy Makers in OPV-Using Countries [internet]. Ginebra, (Suiza): World Health Organization; 2008 Dec [consultado 30 de noviembre de 2011] 11p. Disponible en: http://www.polioeradication.org/content/publications/OPVCessationFrameworkEnglish.pdf

  21. Albrecht RM. Poliomyelitis from a vaccinee. Lancet 1968; 1:1371.

  22. Nkowane BM, Wassilak SGF, Orenstein WA, et al. Vaccine associated paralytic poliomyelitis, United States: 1961-72. JAMA 1987; 257: 1335-1340.

  23. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 1988; 66:739-746.

  24. Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizou H, Nathanson N et al. Circulating vaccine-derivated polioviruses: current state of knowledge. Bull World Health Organ 2004; 82:16-23.

  25. CDC. Outbreak of poliomyelitis – Dominican Republic and Haiti, 2000. MMWR Morb Mortal Wkly Rep 2000;49:1094-1103.

  26. Zurbriggen S, Tobler K, Abril C, Diedrich S, Ackermann M, Pallansch MA, et al. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl Environ Microbiol 2008; 74:5608-5614.

  27. Troy SB, Ferreyra-Reyes L, Huang C, Mahmud N, Lee YJ, Canizales- Quintero S. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a mexican national immunization day. J Clin Microbiol 2011;49:1777-1783.

  28. Duintjer-Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol 2005; 162:358-372.

  29. Salas-Peraza D, Avila-Agüero ML, Morice-Trejos A. Switching from OPV to IPV: are we behind the schedule in Latin America? Expert Rev Vaccines 2010;9:475-483.

  30. Sutter R, Prevots DR, Cochi SL. Introduction of inactivated poliovirus vaccine into oral polio vaccine-using countries. Wkly Epidemiol. Rec 2003; 78: 241-252.

  31. Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011;10:635-644.

  32. World Health Organization. Global Polio Erradication Initiative [Internet] Ginebra (Suiza) 1996- [Consultado 30 de marzo 2012]. Disponible en: http://apps.who.int/immunization_monitoring/en/diseases/poliomyelitis/case_count.cfm

  33. Arya SC, Agarwal N. Global polio laboratory network: future pursuit and commitments. J Clin Virol 2007;38:362-363.

  34. Completion of national laboratory inventories for wild poliovirus containment:WHO Region of the Americas, March 2010. Wkly Epidemiol Rec 2010; 85:329-333.




2020     |     www.medigraphic.com